Vaginal carcinoma
disease diseaseOn this page
Also known as cancer of the vaginacancer of vaginacarcinoma of the vaginacarcinoma of vaginavagina cancervagina carcinomavaginal cancervaginal cancer, NOSvaginal malignant epithelial tumorvaginal malignant epithelial tumour
Summary
Vaginal carcinoma (MONDO:0015867) is a cancer and 115 clinical trials. Top therapeutic interventions include cisplatin, human papillomavirus, l1 protein virus like particles, and belzutifan. A subtype of vaginal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 1 000 000 (Worldwide) [Orphanet-validated]
- Clinical trials: 115
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.36 | Worldwide | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vaginal carcinoma |
| Mondo ID | MONDO:0015867 |
| Orphanet | 180247 |
| DOID | DOID:0050918 |
| NCIT | C3917 |
| UMLS | C0262659 |
| MedGen | 82653 |
| GARD | 0009348 |
| Anatomy (UBERON) | UBERON:0000996 |
| Is cancer (heuristic) | yes |
Also known as: cancer of the vagina · cancer of vagina · carcinoma of the vagina · carcinoma of vagina · vagina cancer · vagina carcinoma · vaginal cancer · vaginal cancer, NOS · vaginal carcinoma · vaginal malignant epithelial tumor · vaginal malignant epithelial tumour
Disease family
This is a subtype of vaginal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › vaginal cancer › vaginal carcinoma
Related subtypes (4): vagina sarcoma, vaginal adenosarcoma, vaginal germ cell malignant tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm
Subtypes (2): vaginal squamous cell carcinoma, vaginal adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 115.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 57 |
| PHASE2 | 22 |
| PHASE1 | 18 |
| PHASE3 | 13 |
| PHASE1/PHASE2 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02466971 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers |
| NCT04422366 | PHASE3 | RECRUITING | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT04895020 | PHASE3 | RECRUITING | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years |
| NCT05027776 | PHASE3 | RECRUITING | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years |
| NCT00003267 | PHASE3 | COMPLETED | Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer |
| NCT00033605 | PHASE3 | COMPLETED | Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis |
| NCT00543543 | PHASE3 | COMPLETED | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) |
| NCT00943722 | PHASE3 | COMPLETED | A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) |
| NCT01047345 | PHASE3 | COMPLETED | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) |
| NCT01087268 | PHASE3 | UNKNOWN | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer |
| NCT03158220 | PHASE3 | COMPLETED | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) |
| NCT04425291 | PHASE3 | COMPLETED | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT05372016 | PHASE3 | COMPLETED | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT04708470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
| NCT05639972 | PHASE1/PHASE2 | RECRUITING | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers |
| NCT05686226 | PHASE2 | RECRUITING | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers |
| NCT05969860 | PHASE2 | RECRUITING | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
| NCT05979610 | PHASE2 | RECRUITING | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies |
| NCT06677190 | PHASE2 | RECRUITING | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin |
| NCT06686043 | PHASE2 | RECRUITING | HPV Vaccine, Imiquimod, and Metformin Combination Trial |
| NCT07407647 | PHASE2 | RECRUITING | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer |
| NCT00002562 | PHASE2 | COMPLETED | Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer |
| NCT00005941 | PHASE2 | COMPLETED | Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer |
| NCT00275353 | PHASE2 | COMPLETED | Effectiveness of an Individualized Symptom Education Program (ISEP) |
| NCT00381888 | PHASE2 | COMPLETED | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
| NCT00520598 | PHASE2 | COMPLETED | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) |
| NCT00545792 | PHASE2 | COMPLETED | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers |
| NCT00551187 | PHASE2 | COMPLETED | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) |
| NCT00905658 | PHASE2 | UNKNOWN | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer |
| NCT00941070 | PHASE2 | COMPLETED | Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer |
| NCT01079832 | PHASE2 | COMPLETED | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies |
| NCT01097239 | PHASE1/PHASE2 | WITHDRAWN | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer |
| NCT01399658 | PHASE2 | COMPLETED | Image-Guided Gynecologic Brachytherapy |
| NCT01585428 | PHASE2 | COMPLETED | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
| NCT01764802 | PHASE2 | COMPLETED | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer |
| NCT02280811 | PHASE1/PHASE2 | COMPLETED | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers |
| NCT03180294 | PHASE2 | COMPLETED | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer |
| NCT03220009 | PHASE2 | WITHDRAWN | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma |
| NCT03439085 | PHASE2 | TERMINATED | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers |
| NCT03634267 | PHASE1 | ACTIVE_NOT_RECRUITING | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 4 |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | 4 | 2 |
| BELZUTIFAN | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| FONDAPARINUX SODIUM | 4 | 1 |
| OCTREOTIDE ACETATE | 4 | 1 |
| PRASTERONE | 4 | 1 |
| VINORELBINE TARTRATE | 4 | 1 |
| TRIAPINE | 3 | 3 |
| BINTRAFUSP ALFA | 3 | 1 |
| ENTINOSTAT | 3 | 1 |
| PERFLUBUTANE | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| EDODEKIN ALFA | 2 | 1 |
| FAPI-46 GA-68 | 2 | 1 |
| CHEMBL4084635 | 0 | 1 |
| CHEMBL3764816 | 0 | 1 |
| CHEMBL5724798 | 0 | 1 |